Birch bark extract (wounds associated with dystrophic and junctional epidermolysis bullosa (EB), patients aged ≥ 6 months)



  • Active Sustance: Birch bark
  • Name: Filsuvez®
  • Therapeutic area: Dystrophic and junctional epidermolysis bullosa (EB)
  • Pharmaceutical company: Amryt Pharma GmbH


Time table:

  • Start: 01.09.2022
  • Publication of assessment: 01.12.2022
  • End of public hearing: 22.12.2022
  • Final decision by G-BA: middle of February 2023


Comparative therapy:

  • No comparative therapy due to orphan drug designation